

Name and institution	<p>apl Prof Dr Oleg Timofeev Philipps-Universität Marburg Institut für Molekulare Onkologie Zentrum für Tumor- und Immunbiologie (ZTI) Hans-Meerwein-Str. 3, 35043 Marburg Tel.:+49(0)06421-28-26288 Fax:+49(0)6421-28-24292 E-Mail: timofeev@staff.uni-marburg.de Web: https://www.uni-marburg.de/en/fb20/departments/zti/imo/staff/timofeev ORCID 0000-0002-3114-6403</p>
Position	Research scientist, Group leader
Date of Birth	06.09.1969, male
Academic career	
11/2022	Professor (apl) at the Philipps-University of Marburg
6/2016	Habilitation at the Philipps-University of Marburg for Molecular Oncology
8/2010-	Senior Post-doc, Group leader at the Institute of Molecular Oncology, Philipps-University of Marburg
11/2008 – 06/2010	Project coordinator, R&D department, Alkor-Bio Group, St.Petersburg, Russia
08/2005 – 11/2008	Post-doc at the Cell Cycle Control and Carcinogenesis group, German Cancer Research Centre, Heidelberg
03/2004 – 02/2005	Guest Scientist, Cell Cycle regulation and Tumorigenesis group, Institute of Molecular and Cell Biology, Singapore
06/2003 – 12/2003	Guest Scientist, Basic Research Laboratory, National Cancer Institute, NIH, Bethesda, USA
02/2002 – 08/2002	Practical student (grantee), Institute of Molecular Biology, Center for Cancer Research and Cancer Therapy, University of Essen
10/2000 – 11/2002	Scientific assistant, Department of Molecular Mecanisms of Cell Differentiation, Institute of Cytology, Russian Academy of Sciences, St.-Petersburg, Russia
Academic degrees	
11/2022	Professor (apl) at the Philipps-University of Marburg
10/2016	Privat-Dozent, Philipps-University of Marburg, Habilitation Thesis “Stress-induced pathways in tumor suppression”
03/2005	Kandidat Nauk (Candidate of Science, Russian equivalent of PhD), Institute of Cytology of Russian Academy of Science (St. Petersburg, Russia), Thesis: “The role of p38 MAPK and Wip1 phosphatase in tumor suppression and tumorigenesis”
University education	
06/2000 – 10/2002	MSc, St. Petersburg State University (St. Petersburg, Russia)

05/2000

BSc, St. Petersburg State University

5/1992 – 5/2000

Study of Biology and Informatics at the St. Petersburg State University and St. Petersburg Industrial College

Publications (last 5 years)

1. Merle N, Elmshäuser S, Strassheimer F, Wanzel M, König AM, Funk J, Neumann M, Kochhan K, Helmprobst F, Pagenstecher A, Nist A, Mernberger M, Schneider A, Braun T, Borggrefe T, Savai R, Timofeev O, Stiewe T “Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase” **Mol Cancer**. 2022 Oct 3;21(1):191 (IF 41.444)
2. Klimovich B, Meyer L, Merle N, Neumann M, König A, Ananikidis N, Keber C, Elmshäuser S, Timofeev O*, Stiewe T “Partial p53 reactivation is sufficient to induce cancer regression” (2022) **J of Experimental & Clinical Cancer Research** *co-senior author (IF 9.95)
3. Klimovich B, Merle N, Neumann M, Elmshäuser S, Nist A, Mernberger M, Kazdal D, Stenzinger A, Timofeev O*, Stiewe T. (2021) p53 Partial Loss-of-Function Mutations Sensitize to Chemotherapy. **Oncogene** doi: 10.1038/s41388-021-02141-5 *co- senior author (IF 8.64)
4. Timofeev O & Stiewe T “Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy” (2021) **Cancers** 13(10):2422 (IF 6.126)
5. Timofeev O “Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments” (2021) **Front Oncol** 11:740578 (IF 4.84)
6. Klimovich B, Stiewe T, Timofeev O. (2020) Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo. **Cell Cycle** 19(1):109-123. (IF 4.53)
7. Timofeev O, Koch L, Niederau C, Tscherne A, Schneikert J, Klimovich M, Elmshäuser S, Zeitlinger M, Mernberger M, Nist A, Osterburg C, Dotsch V, German Mouse Clinic C, Hrabe de Angelis M, and Stiewe T. (2020). Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging. **Cancer Res** 80: 5231-5244. (Highlighted by: Horikawa I. (2020). Balancing and Differentiating p53 Activities toward Longevity and No Cancer? **Cancer Res** 80: 5164-5165. (IF 12.70)
8. Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, Wanzel M, Stiewe T. „mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability“ (2020) **Nat Commun** 11(1):4684 (IF 14.919)
9. Klimovich B, Mutlu S, Schneikert J, Elmshäuser S, Klimovich M, Nist A, Mernberger M, Timofeev O*, Stiewe T*. (2019) Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy. **Proc Natl Acad Sci U S A**. 2019 116(44): 22288-22293. (IF 11.21) * co- senior author
10. Timofeev O, Klimovich B, Schneikert J, Wanzel M, Pavlakis E, Noll J, Mutlu S, Elmshäuser S, Nist A, Mernberger M, Lamp B, Wenig U, Brobeil A, Gattenlohner S, Kohler K, and Stiewe T. (2019). Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. **EMBO J** 38: e102096. (Highlighted by: Manfredi JJ. (2019). p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill. **EMBO J** 38: e103322.) (IF 11.60)
11. Timofeev O & Stiewe T “p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding.” (2017) **Mol Cell Oncol** 4: e1288678 (IF 1.48)